Background: Before the genome-wide association (GWA) era, many hypothesis-driven candidate gene association studies were performed that tested whether DNA variants in genes that had been selected based on prior knowledge about migraine pathophysiology were associated with migraine. Most studies involved small sample sets without robust replication, thereby making the risk of false-positive findings high. Genome-wide marker data of thousands of migraine patients and controls from the International Headache Genetics Consortium provide a unique opportunity to re-evaluate key findings from candidate gene association studies (and other non-GWA genetic studies) in a much larger data set.
Introduction
Disease susceptibility for common disorders, including migraine, is thought to be conferred by a combination of environmental factors and genetic factors that are either common (i.e. with a minor allele frequency (MAF) larger than 5% in the population) or rare. In the past decades, many genetic association studies have been performed by testing DNA variants in dozens of candidate genes in order to identify genetic factors for migraine (1, 2) . Genes were selected based on the hypothesis that the respective pathway was implicated in migraine pathophysiology; e.g. genes that play a role in serotonin and dopamine pathways (3) . The majority of the studies investigated only a single or a limited number of DNA variants per gene and therefore had a low a priori likelihood of targeting the correct variant that confers disease susceptibility. Moreover, rather low numbers of cases and controls (rarely more than 300 per group) were studied, resulting in limited statistical power to evaluate their association. For the majority of the associations no replication of the findings in independent cohorts was provided (for review, see de Vries et al. (1) ). Consequently, many of the associations may in fact represent false-positive findings. Similar experiences have been observed in other common diseases (4) (5) (6) .
Over the last few years, genome-wide association studies (GWAS) have become the state-of-the-art approach to identify genetic factors involved in common disorders. Unlike candidate gene association studies that are hypothesis driven, GWAS are hypothesis free and hypothesis generating in nature. Typically they involve large cohorts of at least several thousand patients and controls and test the association with disease of hundreds of thousands of single nucleotide polymorphisms (SNPs) distributed over the genome (7) . Importantly, initial association findings are always scrutinized by follow-up testing in multiple independent replication cohorts. Therefore, the GWAS approach is less susceptible to false-positive results and more powerful than candidate gene association studies. Two GWA studies that investigated large numbers of migraine cases from clinic-based cohorts and controls have been published (8, 9) . One study investigated migraine with aura (MA) (with 2731 cases and 10,747 controls) and revealed a single genome-wide significant migraine susceptibility locus on chromosome 8q22.1 that pinpointed the MTDH gene as the possible disease-causing gene in this region (8) . The other study investigated migraine without aura (MO) (with 2326 cases and 4580 controls) and yielded four additional migraine susceptibility loci on 1q22, 3p24, 6p24 and 9q33 presenting evidence for involvement of the MEF2D, TGFBR2, PHACTR1 and ASTN2 genes, respectively (9) . The latter study also confirmed genetic associations of SNPs in the TRPM8 and LRP1 genes (2q37 and 12q13, respectively) that had previously been identified as migraine susceptibility loci in a population-based GWA study (with 5122 cases and 18,108 controls) (10) . A recent large meta-analysis (with 23,285 cases and 95,425 controls) that studied patients from clinic-based as well as population-based cohorts confirmed these loci and provided evidence for five additional migraine susceptibility loci (11) . Notably, none of these genome-wide significant gene loci overlapped with genes that had been selected for candidate gene association studies in migraine.
The availability of GWAS data provides a unique opportunity to re-evaluate key findings from previous genetic studies in a much larger data set. We investigated 27 genes. Twenty-one genes were previously reported to be associated with migraine in candidate genes-based association studies. Three genes had been identified by positional cloning studies in families with familial hemiplegic migraine (FHM), a monogenic subtype of MA (12) (13) (14) . Three genes came from direct sequencing of candidate genes in families and patients with monogenic migraine or common migraine (15) (16) (17) . As the majority of the original studies investigated migraine patients who had been collected via specialized headache centers (i.e. patients who are clinic-based), we restricted our investigations to GWAS data of clinic-based migraine patients only (8, 9, 11) .
Materials and methods
Selection of candidate genes for re-evaluation in the International Headache Genetics Consortium (IHGC) GWA data set Genes were selected for re-evaluation in the IHGC GWAS data set based on the results of a literature search of candidate gene association studies in migraine. We included studies that had investigated at least 300 migraine patients and 300 controls of Caucasian origin. From these studies, we selected only those genes for which at least nominally significant, uncorrected p values (p < 0.05) were reported for one or more SNPs (see list of genes in Table 1 ). In addition, we selected genes from non-GWA genetic studies of migraine, namely the three FHM genes (CACNA1A (12), ATP1A2 (13) and SCN1A (14)) and three genes in which possibly causal mutations had been identified by a candidate gene sequencing approach, i.e. SLC1A3 (which encodes the EAAT1 glutamate transporter) (15) , SLC4A4 (twhich encodes the NbCe1 protein) (16) , and KCNK18 (which encodes the TRESK protein) (17) ( Table 2) .
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GWAS data sets
GWAS data of 2849 MA patients and 2326 MO patients from five clinic-based cohorts were collected via specialized headache centers in Finland, the Netherlands, and Germany (8, 9, 11) . Migraine diagnoses were based on a combination of questionnaires and/or individual interviews according to the International Classification of Headache Disorders, second edition (ICHD-II) guidelines (38) (Table 3 ).
Since the patients of nearly all candidate gene association studies came from clinic-based cohorts, we chose to investigate GWAS data only from clinic-based cohorts and not from population-based cohorts. An additional reason for including only clinic-based cohorts is that phenotypic information is less detailed and/or accurate in population-based cohorts, which would probably increase clinical and genetic heterogeneity. In all GWAS samples, standard quality control measures were applied; SNPs with call rates <97%, MA: migraine with aura; MO: migraine without migraine; NS: not significant; À: not tested/not available; SNP: single nucleotide polymorphism; Ins: insertion; Del: deletion; VNTR: variable number of tandem repeats. a Number of cases and b p values are given for all migraine cases combined or, when specified between brackets, for migraine with aura cases only and/or migraine without aura cases only.
MAF <1% and/or excessive deviation from Hardy-Weinberg equilibrium (with p < 10 À6 ) in either cases or controls were excluded. Individuals with a genotyping rate <97% were excluded from the analyses (for more details, see Anttila et al. (11)). Genome-wide marker data from 13,972 individuals from several pre-existing non-overlapping control cohorts that were population-matched to the cases were used as controls. The majority of the control cohorts were unselected for migraine status, implicating that they are expected to contain cases at the same frequency as the general population (Table 3 ). In the meta-analysis, SNPs missing from one of the studies, those with a MAF < 1%, and/or those showing excess heterogeneity (I 2 > 0.75) were excluded.
Power calculation and significance threshold
Data for the selected genes were extracted from the existing GWAS data from an interval containing the candidate gene and the flanking region 500 kb in each direction, to have a reasonable chance of covering possible regulatory effects for the targeted genes. The threshold for evaluating the significance of SNPs located in the tested gene regions was 2.19 Â 10 À6 , based on a Bonferroni correction for the number of unique SNPs that were tested (0.05/22,774). Our GWAS sample (5175 cases and 13,972 controls) has 99% power to detect association with an SNP under the assumption of an allele frequency (AF) of at least 0.05 and a relative risk of 1.5 or higher (allelic test, Genetic Power Calculator (http://pngu.mgh.harvard.edu/$purcell/gpc) (19) ). These thresholds are in line with published candidate gene association studies. On a more stringent level, we have 84% power to detect a variant with a relative risk of 1.4. See Supplemental  Table 1 for power calculations at a range of different allele frequencies (0.05-0.4) and relative risks (1.15-1.5).
Effect size estimation
We used the Genetic Power Calculator to estimate the genotype frequencies for a marker with similar MAF and odds ratio (OR) as the MTHFR C677T risk allele, while assuming a disease prevalence of 12%, and using the sample size of the current study (5175 cases and 13,972 controls). A chi-square test for the resulting genotype frequencies was converted to a p value using a two-degree of freedom (df) chi-square test.
Results
We used GWAS data of clinic-based migraine patients (8, 9, 11 ) to re-evaluate 21 genes from migraine candidate gene association studies that had analyzed at least 300 migraine cases and controls and yielded associations of at least nominal p values (Table 1) . Six additional genes were included that came from other non-GWA studies, i.e. either candidate gene sequencing 
SLC4A4/NBCe1
Homozygous mutations in SLC4A4 were reported in two sisters with reported hemiplegic migraine, in addition to proximal renal tubular acidosis and ocular abnormalities, and presented first evidence for SLC4A4 as a migraine gene. SLC4A4 encodes the Na þ -NCO À 3 cotransporter NBCe1.
Suzuki et al. 2010 (16) KCNK18/TRESK A mutation in KCNK18 in a single family with familiar migraine was identified in a candidate gene sequencing approach and presented first evidence for KCNK18 as a migraine gene. KCNK18 encodes for the ion channel TRESK.
Lafrenière et al. 2010 (17) FHM: familial hemiplegic migraine; SHM: sporadic hemiplegic migraine; MA: migraine with aura.
de Vries et al. Table 2 ), surpassed the significance threshold (Table  4 , Supplemental Information). When analyzing MA and MO together, the best p value was seen for SNP rs805287 (p ¼ 1.08 Â 10 À4 ) that is located within the surrounding region of the TNFA and LTA genes. However, this SNP is located in a gene-dense region over 130 kb downstream of both genes (Figure 1(a) ) and lies within the major histocompatibility complex locus, where overall levels of noise are higher because of the complex linkage disequilibrium structure (49) . When analyzing MA and MO separately, for MA, again the best p value was observed with an SNP (rs630379; p ¼ 9.68 Â 10 À6 ) at the border of the region surrounding the TNFA and LTA genes (Supplemental Information). For MO, the best p value was seen for an SNP (rs13024246, p ¼ 2.76 Â 10 À5 ) located in the FSHR gene region (Figure 1(b) ) but this SNP was located far away from the originally selected gene. Only one gene region, namely that of the DRD3 gene, showed a potentially interesting peak (with best associated SNP rs1486008, p ¼ 2.88 Â 10 À4 ; OR ¼ 1.19) within the previously implicated migraine gene (Figure 1(c) ).
Although the chance of observing associations that are gender-specific is limited, as the vast majority of the migraine patients are women, we performed a genderspecific analysis for the total migraine group. Analyzing males and females separately did not reveal SNPs with gender-specific signals surpassing the significance threshold (Supplemental Table 3 ).
Discussion
For this study, we used the data of clinic-based GWA cohorts from the IHGC (8, 9, 11) to re-evaluate key findings from previously published candidate gene association studies (and other genetic non-GWAS studies) in migraine. Our study included GWAS data from 5175 migraine patients and 13,972 controls and shows no significant association with migraine for any of the 27 genes (Table 4 ), despite the fact that our study had sufficient power (>95%) to significantly detect genetic association signals for variants with an MAF >0.05 and a relative risk >1.4, as commonly presumed in the much smaller migraine candidate gene association studies. Only a few single SNPs for some of the 27 selected gene regions showed moderate evidence of association. Notably, none of the p values of the SNPs reported in the original publications surpassed the significance threshold (Supplemental Table 2 ), nor translated to the originally reported effect sizes. For example, the T-allele of the C677T polymorphism in the MTHFR gene, which showed significant association with migraine in various candidate gene association studies, did not show up in our study. Assuming an effect size of 1.5, which is in line with previously reported effect sizes for this variant in migraine (18) (19) (20) (21) 50) , and an MAF of 31% in the European population (51), our study would have produced a p value below 1.46 Â 10 À63 . However, the T-allele showed no association with migraine in our study (p ¼ 0.56 for migraine; p ¼ 0.51 for MA; p ¼ 0.11 for MO); the lowest observed p value in the MTHFR gene region in our study was 7.18 Â 10 À4 for SNP rs11121783. Also for the other SNPs of the originally reported associations, our study should have produced low p values; well below the set threshold of 2.19 Â 10 À6 , if the reported effect sizes would have replicated. These poor replication results indicate the limited value of small-scale genetic association studies at the single-gene or single-marker level, and emphasize the importance of using large, well-powered studies that are properly designed. This finding is in line with a recent review that supports the statistical observation that low power due to small sample sizes not only decreases the chance to detect a true effect, but also increases the chance that a significant finding does not reflect a true effect (52) .
Based on current knowledge of effect sizes of common variants for many common diseases, the vast majority of the candidate gene association studies in the literature lacked sufficient power to detect an effect that can be realistically expected for a common allele in a common disorder like migraine. Therefore, the most probable reason for the lack of replication is that the results of the candidate gene association studies most likely represent false-positive findings. Although we did not show significant evidence for any of the genes previously implicated in common migraine as genetic migraine risk factors, we cannot, however, exclude the possibility that some of the previous findings are truepositive findings reflecting effects specific to a particular patient pool (such as individual families, in whom alleles that are rare in the general population can predominate). Possible additional reasons that could explain why we did not detect associations are that: (1) rare variants that may play a role may not be captured, either in candidate gene association studies or GWAS platforms, because of specific LD patterns that are not sufficiently reflected in the surrounding common markers; or (2) variants located in these candidate gene regions may play a role that have effect sizes too low to be detected, even with the current sample size, and will surface only with sample sizes de Vries et al.
on the order of several hundreds of thousands cases and controls.
In conclusion, our analysis shows no evidence for the involvement of any of the selected 27 genes in migraine pathophysiology of common migraine. For future studies, other approaches should be considered to identify migraine susceptibility genes. This finding is in line with experiences of candidate gene association studies in other common diseases (53) .
Article highlights
. Re-evaluation of previously reported migraine candidate gene hits shows no evidence for involvement in migraine pathology in a genome-wide association (GWA) data set. . Small-scale genetic association studies lacking proper replication appear of limited value. 
